(Q38163048)

30 August 2017

title

A review of FDA-approved treatment options in bipolar depression (English)

1 reference

30 August 2017

1 reference

1

Roger S McIntyre

1 reference

30 August 2017

Danielle S Cha

2

1 reference

30 August 2017

Rachael D Kim

series ordinal

3

1 reference

30 August 2017

Rodrigo B Mansur

series ordinal

4

1 reference

30 August 2017

publication date

15 November 2013

1 reference

30 August 2017

1 reference

30 August 2017

volume

18 Suppl 1

1 reference

30 August 2017

page(s)

4-20; quiz 21

1 reference

Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Long-term symptomatic status of bipolar I vs. bipolar II disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

inferred from DOI database lookup

7 January 2021

based on heuristic

Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852913000746

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S1092852913000746

1 reference

30 August 2017

1 reference